The MFN executive order may result in the US losing its place as the friendliest market for innovation.

GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like ...

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s ...

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...

AbbVie officially began construction on its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, ...

AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a ...

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.